Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814988 | 0.92 | HSD11B1 (0.56) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL25024431 | 0.89 | CTSK (0.49) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL17323937 | 0.87 | EPHX2 (0.57) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL4953395 | 0.87 | CTSK (0.52) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL4992424 | 0.86 | CTSK (0.47) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL14417805 | 0.85 | CTSK (0.51) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL13459453 | 0.85 | CTSK (0.51) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL12661411 | 0.85 | CTSK (0.51) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 | |
| SCHEMBL28634903 | 0.85 | CA1 (0.49) | CTSKHSD11B1CYP2C9EPHX1CA1 | |
| SCHEMBL4760751 | 0.84 | CTSK (0.50) | CTSKALDH1A1HSD11B1CYP2C9EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-03-27 | — | — | US | disclosed |
| WO-2024155112-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | UPPTHERA, INC. (KR) | 2024-07-25 | — | — | WO | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384521-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2008033562-A2 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CTSK 571/4885ALDH1A1 4300/4885HSD11B1 2215/4885 |
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CTSK 1471/4885ALDH1A1 4008/4885HSD11B1 2777/4885 |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | CTSK 4805/4885ALDH1A1 2617/4885HSD11B1 4300/4885 |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CTSK 1058/4885ALDH1A1 3592/4885HSD11B1 1934/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CTSK 571/4885ALDH1A1 4300/4885HSD11B1 2215/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CTSK 1471/4885ALDH1A1 4008/4885HSD11B1 2777/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | CTSK 1058/4885ALDH1A1 3592/4885HSD11B1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.